BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Launches World’s First Iris Authentication Feature in Smart-glasses Payment Solution12.11.2025 08:48:00 CET | Press release
Alipay+ GlassPay, Ant International’s smart glasses-embedded payment solution, will add iris authentication to its security verification capabilities, alongside voiceprint authentication The enhanced solution improves consumer checkout experience and merchant payment success rate, and opens a new channel for personalised customer interaction Ant International continues to push the frontiers of payment technology, adding to recent developments including AI-powered agentic payments and NFC-based integration of QR and card payments In a global first, Ant International, a leading global digital payment, digitisation, and financial technology provider, has added iris authentication features to Alipay+ GlassPay, its AR glasses-embedded payment solution, through partnerships with leading smart glasses producers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111892620/en/ The enhanced solution improves consumer checkout experien
Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support12.11.2025 08:04:00 CET | Press release
Exstent, a UK-based medical device company, developing personalised external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth. Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President and CEO at Endologix, guiding the company through transformation, portfolio growth, and the 2021 acquisition of PQ Bypass. Earlier in his career, Matt was Professor of Vascular Surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His experience in integrating novel vascular technologies into established commercial frameworks aligns closely with Exstent’s strategic direction. “Exstent’s personalised external aortic support is a meaningful advance in managing ascending aortic disease,” said Matt Thompson, CEO of Exstent. “It preserves the
Ant International’s Antom Launches AI‑Powered MSME App for Finance and Business Operations12.11.2025 03:00:00 CET | Press release
The EPOS360 App integrates POS system, payments, banking, lending, and growth support into one platform to help MSMEs start, grow, and scale efficiently.The app embeds an AI copilot to simplify operations and turn business information into actionable insights.Supported by ANEXT Bank, one of the first digital banks in Singapore, MSMEs can access credit faster and manage financing with greater ease. Antom, a leading provider of merchant payment and digitisation services under Ant International, today announced EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium-sized enterprises (MSMEs) move from setup to scale efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111066634/en/ The AI-powered EPOS360 provides POS system, payments, banking, lending and other growth-enabling services, offering customised support to help MSMEs ope
Venture Global and Mitsui Announce 20-Year LNG Sales and Purchase Agreement12.11.2025 00:00:00 CET | Press release
Venture Global’s third long-term contract with a Japanese company6.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Mitsui & Co., Ltd. of Japan announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Mitsui will purchase 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2029. “Venture Global is honored to announce our new partnership with Mitsui, a distinguished leader in the LNG industry, to further increase the flow of U.S. LNG to Japan and the global market,” said Mike Sabel, CEO of Venture Global. “This collaboration between our two companies will strengthen energy security, enhance the balance of trade, and deepen the long-standing ties between our nations. This agreement builds upon our existing long-term relationships with Japanese companies, and we are deeply grateful for their continued trust in Venture Glob
Lattice to Showcase Advanced Industrial and Edge AI Solutions at SPS 202511.11.2025 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its participation in the upcoming SPS 2025, taking place on November 25 – 27, 2025 in Nuremberg, Germany. Lattice will deliver a presentation on secure motor control solutions and technology demonstrations with industry partners focused on advanced embedded vision and machine learning applications for the Industrial market. Who: Lattice Semiconductor What / When (GMT+2):Nov. 25 – 27, 2025: Embedded Vision and Machine Learning Demo Showcase EtherCAT Technology Group Booth (Hall 5, #310) Exor booth (Hall 9, #375) Nov. 25, 2025: Tech Talk (11 – 11:30 a.m.) Secure Connected Motion Control Platform for AC Motors: A Collaborative Innovation by Analog Devices and Lattice Semiconductor Where: Nuremberg Messe, Nuremberg, Germany SPS (Smart Product Solution) 2025 is one of the world’s leading trade fairs for industrial automation and digitalization. It showcases the entire spectrum of smart and digital autom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom